Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.